Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
Regulatory approvals in three major markets confirm commercial execution for the 2026-2027 season.
What changed
Regulatory approvals in three major markets confirm commercial execution for the 2026-2027 season.
Why it matters
Regulatory approvals in three major markets confirm commercial execution for the 2026-2027 season. — impact context not separately stored; see What changed.
← Dashboard
Aug 28, 2026 03:55 PM ET